Sermorelin Dosage and Side Effects: A Physician-Reviewed Guide

Sermorelin has never had an FDA-approved adult dose. The only sermorelin doses that ever appeared on a United States label were pediatric: 30 micrograms per kilogram of body weight injected under the skin once nightly for growth hormone deficiency in children, and a single 1 microgram per kilogram intravenous dose used as a diagnostic test of pituitary function. Both products, Geref and Geref Diagnostic, were discontinued in 2008. The 100 to 500 microgram nightly figures circulating in online dosage charts come from compounding practice, not from an approved label, and the largest published adult trial used 2 mg nightly, several times more than those charts suggest, without changing IGF-1 or body composition.

That gap between what is published and what is marketed is the single most useful thing to understand before you look at any sermorelin dosage chart. This guide sets out the doses that actually have evidence behind them, what the adult research found, the side effect profile in two tiers, and who should not use sermorelin at all.

What sermorelin doses have ever appeared on a US label?

Sermorelin is a 29 amino acid analogue of human growth hormone-releasing hormone, or GHRH. It is the shortest synthetic peptide that retains the full biological activity of natural GHRH, which is documented in the review by Prakash and Goa published in BioDrugs in 1999. In plain terms: sermorelin binds the GHRH receptor on your pituitary gland and asks the gland to release a pulse of your own growth hormone, rather than replacing growth hormone from outside.

Two formulations were approved by the US Food and Drug Administration, in 1990 and 1997, and both were discontinued in 2008. Here is what their labels covered.

Notice what the second column does and does not contain. Every number with a label behind it is weight-based and belongs to a pediatric or diagnostic use. There is no row for a healthy 45 year old who wants better sleep and recovery, because no regulator has ever evaluated a dose for that purpose.

Why the sermorelin dosage charts you find online are not protocols

Search for a sermorelin dosage chart and you will find tidy tables: 100 mcg nightly to start, 200 to 300 mcg as a standard adult dose, up to 500 mcg for body composition goals, cycled for three to six months. Those figures are real in the sense that compounding pharmacies and clinics use them. They are not a protocol in the sense that a label or a guideline is a protocol. No regulatory body reviewed them, no trial established them, and they vary from one clinic to the next.

Run the arithmetic against the only weight-based dose ever approved and the gap is striking. For an 80 kilogram adult, the pediatric label dose of 30 mcg per kilogram works out to roughly 2.4 mg nightly. A commonly quoted clinic dose of 200 mcg for the same person is about 2.5 mcg per kilogram, around one twelfth of that. Neither figure is wrong, because they were set for different purposes in different populations. But it means the charts are not a scaled-down version of an approved regimen. They are a separate convention.

This is also why a sermorelin dosage calculator cannot safely tell you how many units to draw. The micrograms in each unit on your syringe depend entirely on how much bacteriostatic water was used to reconstitute your particular vial, which is set by the pharmacy or the prescription. The same 0.1 mL can be 100 mcg or 500 mcg. That number comes from your prescriber, not from a web form.

What the adult research actually used, and what it found

The most informative adult study of this peptide is Vittone and colleagues, published in Metabolism in 1997. Eleven healthy, non-obese men aged 64 to 76 with low baseline IGF-1 self-injected 2 mg of GHRH (1-29) subcutaneously every night for six weeks at home. The dose was far above anything in a clinic chart, the population was exactly the one anti-aging marketing targets, and the measurements were thorough.

The honest summary of the results:

• Growth hormone release did rise. Mean nocturnal GH release, the area under the GH peak and GH peak amplitude all increased, with no change in pulse frequency. The mechanism works.
• IGF-1 did not change. Neither did IGF binding protein-3 or growth hormone binding protein. IGF-1 is the downstream hormone that mediates most of growth hormone’s effects on tissue, so this matters.
• Body composition did not change. Weight, body mass index, waist to hip ratio and DEXA measures of muscle and fat were all unchanged, as were glucose, insulin, lipids and muscle histology.
• Two of six strength measures improved, upright row and shoulder press, along with an abdominal endurance test.
• No significant adverse effects were observed over the six weeks.

The authors’ own conclusion was that single nightly doses appear less effective than multiple daily doses at producing growth hormone or IGF-1 mediated effects. In other words, the once-nightly bedtime schedule that nearly every clinic uses is the schedule that underperformed in the study.

There is a second honest limit worth stating, from the Prakash and Goa review. Even in sermorelin’s approved pediatric indication, gains in height velocity at 30 mcg per kilogram per day were smaller than those achieved with the same weight-based dose of somatropin, and the effect of long-term sermorelin on final adult height was never determined. A peptide that stimulates your own gland is more physiologic than injecting growth hormone. Physiologic is not the same as more effective.

How sermorelin is given: route, timing, and injection sites

Sermorelin is a subcutaneous injection, given into the fat layer just under the skin with a short insulin-style needle. Dosing at bedtime is standard and has a rationale: growth hormone is released in pulses that are largest during early deep sleep, so a bedtime dose is timed to reinforce a pulse that is already due rather than create one at an odd hour.

Mayo Clinic’s drug information, provided by Merative Micromedex, advises rotating the injection site with each dose, using the abdomen, hip, thigh or upper arm in turn, and keeping a simple record of date and location so you do not reuse the same spot. Repeatedly injecting one area is what produces the lumps and local irritation people complain about. The same source advises storing the medication in the refrigerator and not freezing it.

Beyond that, the specifics belong to your prescription. Reconstitution volume, concentration, how long your vial is good for after mixing and whether you run continuous or cycled dosing are all decisions a licensed provider makes with your labs in front of them. If you are weighing growth hormone peptides generally, our guide to sermorelin vs ipamorelin vs CJC-1295 explains how the three differ mechanically, and the tesamorelin dosage guide walks through what a GHRH analogue looks like when it does have a current FDA label to quote.

What are the side effects of sermorelin?

Sermorelin’s side effect picture splits cleanly into two tiers, and most pages online publish only the first. Both are worth reading, because they describe different situations: ordinary dosing, and sustained growth hormone excess.

Tier one: common, mild, and local

These are the effects documented in the approved-label era. Mayo Clinic’s drug information lists injection-site pain, redness or swelling as the most common; itching and difficulty swallowing as rare; and dizziness, flushing, headache, sleepiness and restlessness as other rare effects. The Prakash and Goa review reports transient facial flushing and injection-site pain as the two most frequently reported adverse events across intravenous single doses and repeated nightly subcutaneous doses alike. In the six-week adult trial by Vittone and colleagues at 2 mg nightly, no significant adverse effects were observed.

Tier two: the risks tied to sustained growth hormone excess

The second tier is not about sermorelin the molecule. It is about what happens when growth hormone is pushed high for a long time, which is the scenario in unsupervised or performance-driven use. The US Anti-Doping Agency’s own patient-facing material on sermorelin describes swelling and fluid build-up in the arms, legs and face; joint and nerve pain; insulin resistance with an increased risk of developing diabetes; and, with chronic growth hormone excess, hypertension, cardiac enlargement and potentially cardiomyopathy. It also notes that product obtained from unregulated online or black-market sources may be contaminated or mislabeled, which is a risk entirely separate from the peptide itself.

The practical point is that the top row of that table is a reason to adjust your injection technique, while the bottom row is the reason medical supervision and repeat bloodwork exist. Comprehensive blood testing including a baseline and follow-up IGF-1 and a fasting glucose is how a provider separates a peptide that is working from one that is quietly pushing your metabolism in the wrong direction.

Who should not use sermorelin?

Screening is not a formality on the growth hormone axis. Sermorelin is generally considered inappropriate, or requires evaluation first, in the following situations:

• Active cancer or a history of cancer. Growth hormone and IGF-1 are growth signals, so therapies that raise them are conventionally avoided in active malignancy. This is clinical caution rather than a demonstrated risk from sermorelin specifically.
• Pregnancy and breastfeeding. There are no adequate studies establishing infant risk.
• Untreated or undertreated hypothyroidism. Mayo Clinic’s drug information specifically notes that an underactive thyroid can interfere with the effects of sermorelin, which means thyroid status should be checked and corrected before judging whether a peptide is working.
• Diabetes or impaired glucose tolerance. Growth hormone reduces insulin sensitivity, so glucose needs monitoring.
• A known allergy to sermorelin or any component of the formulation.
• Competitive athletes subject to anti-doping testing. See the next section.
• Anyone treating a diagnosed condition. Sermorelin is not a treatment for any disease in adults, and persistent fatigue, poor sleep or unexplained weight change deserve a proper medical work-up first, not a peptide.

Sermorelin is also not a testosterone therapy and does not raise testosterone. If low testosterone is the real question, that is a separate hormonal axis assessed through men’s health and hormone optimization, and our comparison of TRT and peptides for men over 40 explains why the two are not substitutes.

Is sermorelin prohibited in sport?

Yes. The US Anti-Doping Agency lists sermorelin as a prohibited substance, on the basis that boosting endogenous growth hormone production can enhance muscle growth, endurance and recovery. A therapeutic use exemption is described as highly unlikely. For anyone in a tested sport, and for the entertainment and performance professionals who do get tested under contract, that fact matters more than any dosing question, and it almost never appears on a clinic’s sermorelin page.

Is sermorelin FDA approved, and why is availability complicated?

Sermorelin was approved, and is no longer. The FDA’s Drugs@FDA record for Geref, application NDA 020443, lists both strengths as discontinued, and carries a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. That distinction is important and widely misreported: the withdrawal was a commercial decision, not a safety signal.

The compounding picture is more nuanced than the usual shorthand suggests. Sermorelin does not appear on the FDA’s published list of bulk drug substances for use in compounding that may present significant safety risks, and it has not been added to the final 503A bulks list either. Its availability therefore depends on what compounding pharmacies can lawfully source and prepare, which has shifted over the past few years. Generational Health’s peptide therapy menu reflects the current supply reality, and sermorelin is not currently on it. Patients asking about growth hormone support are most often prescribed CJC-1295 with ipamorelin or tesamorelin instead, after evaluation.

If you are exploring oral alternatives, note that MK-677 (ibutamoren) is often discussed in the same conversation despite not being a peptide at all, and our quick guide to peptides and NAD+ sets out the broader categories.

Medical Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Sermorelin is not FDA-approved for any adult indication; no adult dose has ever been approved, and any adult use is off-label and compounded. It must be prescribed and supervised by a licensed healthcare provider following an individual evaluation, and it is not appropriate for everyone, including during pregnancy, in people with active cancer, and in athletes subject to anti-doping rules. Compounded medications are not FDA-approved, and the FDA does not verify the safety or effectiveness of compounded drugs. Dosing figures in this article are reported from published labels and peer-reviewed literature for educational context and are not a recommendation or a protocol. Individual results may vary. Sermorelin is not currently offered at Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills. Always consult a qualified healthcare provider before beginning any new treatment.

Frequently asked questions

Is it safe to take sermorelin?

In its approved era, at labeled doses and under medical supervision, sermorelin was well tolerated: the most common problems were injection-site pain and transient facial flushing, and the one six-week adult trial at 2 mg nightly reported no significant adverse effects. What is not established is long-term safety in healthy adults taking it for years for anti-aging purposes, because that study has not been done. The risks that do appear in the literature cluster around sustained growth hormone excess and around product from unregulated sources, which is why supervision and periodic labs matter more here than the specific number of micrograms.

What should you not take with sermorelin?

The clearest documented interaction is not a drug but a condition: Mayo Clinic’s drug information notes that an underactive thyroid can interfere with sermorelin’s effects, so thyroid function should be assessed and treated first. Beyond that, give your provider a complete list of every prescription, over-the-counter medication and supplement you take, including anything else acting on the growth hormone axis, and discuss alcohol and tobacco use. Stacking multiple growth hormone secretagogues without supervision is how people end up in the growth hormone excess tier of side effects.

What happens when you stop taking sermorelin?

Growth hormone output returns toward your own baseline, and any perceived benefit in sleep or recovery fades over the following weeks. Because sermorelin stimulates your own pituitary through the GHRH receptor rather than replacing growth hormone from outside, it is not expected to suppress your own production the way exogenous growth hormone can. No withdrawal syndrome has been described, and no formal discontinuation studies exist in healthy adults, so the honest answer is that stopping appears uneventful but has not been studied systematically.

Is sermorelin a steroid?

No. Sermorelin is a 29 amino acid peptide analogue of growth hormone-releasing hormone. It acts on the growth hormone and IGF-1 axis, not on androgen receptors, and it does not raise testosterone. It is prohibited in sport, but prohibited and anabolic steroid are not the same category.

How much sermorelin per day is typical?

Clinics and compounding pharmacies commonly work in the range of roughly 100 to 500 micrograms once nightly for adults, but it is worth being precise about what that range is: a convention, not an approved dose. The only weight-based dose ever on a US label was 30 micrograms per kilogram nightly in children, and the main adult trial used 2 mg nightly. Your dose is set by a prescriber using your labs, your history and the concentration of your specific vial.

Where do you inject sermorelin?

Subcutaneously, into the fat layer under the skin, rotating between the abdomen, hip, thigh and upper arm so that no single site is used repeatedly. Mayo Clinic’s drug information recommends keeping a brief record of the date and site of each injection to make rotation easy to track, and avoiding scarred or inflamed areas. The medication is stored in the refrigerator and should not be frozen.

Does sermorelin cause cancer?

There is no evidence that sermorelin causes cancer, and it has not been studied for that question. The reason it is avoided in anyone with active or previously treated malignancy is different and more cautious: growth hormone and IGF-1 are signals that promote cell growth, so clinicians conventionally keep the growth hormone axis quiet in that setting rather than stimulate it. If you have a cancer history, this is a conversation for your oncologist as well as your prescriber.

Where to go from here

If the question behind your search is really whether a growth hormone peptide could help you, the useful next step is not picking a number off a chart. It is a consultation and a baseline IGF-1, so that whatever you start can be measured against something. Generational Health offers physician-supervised peptide therapy in Beverly Hills, a short distance from Cedars-Sinai, with in-clinic and concierge appointments, and our clinical team will tell you plainly when the evidence does not support what you are hoping for. Request a consultation to review your goals, your labs and your history.

Written and medically reviewed by Biana Borchenko, FNP-BC, Family Nurse Practitioner, Board-Certified, with fellowship training through the American Academy of Anti-Aging Medicine (A4M), at Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills. Biana leads peptide and hormone optimization protocols at the clinic, where every peptide plan begins with a full consultation, a review of medical history and laboratory work, and a clear discussion of expected outcomes and limitations.

Sources cited in this article: Prakash A, Goa KL. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs, 1999;12(2):139-157. Vittone J, Blackman MR, Busby-Whitehead J, et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism, 1997;46(1):89-96. Mayo Clinic, “Sermorelin (injection route)”, drug information provided by Merative Micromedex. US Food and Drug Administration, Drugs@FDA record for Geref, NDA 020443. US Food and Drug Administration, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” US Anti-Doping Agency, “What Should Athletes Know About Sermorelin?”